Biofrontera

Biofrontera Net Tangible Assets

The Net Tangible Assets of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 14.91 M EUR. In the previous year, Net Tangible Assets was 17.86 M EUR — a change of -16.53% (lower).

Net Tangible Assets

14.91 MEUR

YoY

-16.53%

Last updated:

Net Tangible Assets of Biofrontera is 2025 14.91 M EUR. Net Tangible Assets of Biofrontera was 2024 17.86 M EUR. It decreases by -16.53% lower compared to the previous year.

The Biofrontera Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
16.36 M EUR
Jan 1, 2019
9.96 M EUR
Jan 1, 2020
7.38 M EUR
Jan 1, 2021
56.29 M EUR
Jan 1, 2022
19.14 M EUR
Jan 1, 2023
18.83 M EUR
Jan 1, 2024
17.86 M EUR
Jan 1, 2025
14.91 M EUR
The Biofrontera Net Tangible Assets history
YEARNet Tangible AssetsYoY
14.91 MEUR-16.53%
17.86 MEUR-5.17%
18.83 MEUR-1.61%
19.14 MEUR-66.00%
56.29 MEUR+663.21%
7.38 MEUR-25.92%
9.96 MEUR-39.14%
16.36 MEUR+383.76%
3.38 MEUR-78.66%
15.84 MEUR-429.42%
-4.81 MEUR+22,801.86%
-20,999.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Net Tangible Assets of Biofrontera is 14.91 M EUR in 2025.

Net Tangible Assets of Biofrontera changed from 17.86 M EUR to 14.91 M EUR, representing a -16.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biofrontera

All Key Metrics — Biofrontera